Investment analysts at StockNews.com began coverage on shares of OncoSec Medical (NASDAQ:ONCS – Get Rating) in a research note issued on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.
OncoSec Medical Stock Performance
Shares of ONCS opened at $0.22 on Friday. The company has a 50 day moving average price of $0.69 and a 200-day moving average price of $1.50. OncoSec Medical has a fifty-two week low of $0.18 and a fifty-two week high of $20.68. The stock has a market capitalization of $1.00 million, a PE ratio of -0.01 and a beta of 1.99.
Institutional Investors Weigh In On OncoSec Medical
Several hedge funds have recently modified their holdings of ONCS. Bank of New York Mellon Corp lifted its position in shares of OncoSec Medical by 653.7% in the 1st quarter. Bank of New York Mellon Corp now owns 386,074 shares of the biotechnology company’s stock worth $444,000 after purchasing an additional 334,849 shares during the period. Renaissance Technologies LLC lifted its position in OncoSec Medical by 48.8% during the second quarter. Renaissance Technologies LLC now owns 72,898 shares of the biotechnology company’s stock valued at $54,000 after acquiring an additional 23,900 shares during the last quarter. Two Sigma Investments LP purchased a new stake in OncoSec Medical during the fourth quarter valued at approximately $35,000. Finally, FNY Investment Advisers LLC purchased a new stake in OncoSec Medical during the first quarter valued at approximately $272,000.
OncoSec Medical Company Profile
OncoSec Medical, Inc is a biotechnology company focused on designing, developing and commercializing therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor.
Recommended Stories
- Get a free copy of the StockNews.com research report on OncoSec Medical (ONCS)
- MarketBeat Week in Review – 6/12 – 6/16
- Micron Building Goodwill In Asia, Near $2 Billion Investment
- Is Twilio On The Verge Of A Comeback?
- Broadcom: All-Time Highs But Still Good Value
- Leverage AI And Build A Fortress Portfolio With Adobe
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.
